Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
ConditionAsthma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNational Jewish Health
About this trial
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.
Eligibility criteria
Qualifiers
Informed Consent: Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.
Gender and Age: Male or female subjects >18 years old
A biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation;
Neuropathy, mono or poly (motor deficit or nerve conduction abnormality);
Disqualifiers
Hypereosinophilic Syndrome
Wegener's Granulomatosis
Malignancy
Parasitic disease
Trial design
Treatments tested in this trial
- Reslizumab
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
National Jewish Health
Lead sponsor
Teva Pharmaceuticals USA
Collaborator
Source ClinicalTrials.gov